Перспективы применения ингибиторов IX и XII изоформ карбоангидразы в онкологии

Изоформы IX и XII карбоангидразы человека играют ключевую роль в поддержании кислотно-основного равновесия в солидных опухолях, формируя благоприятное микроокружение для роста, инвазии и метастазирования опухолевых клеток. В последние несколько лет рядом научных групп опубликованы результаты о том, что ингибирование изоформ IX и XII значительно повышает эффективность классической химиотерапии, позволяет подавлять резистентность опухолевых клеток к химиотерапии и повысить их чувствительность к применяемым препаратам (в т.ч. снижение дозы цитостатиков). В обзоре нами проведен анализ научной литературы о роли изоформ IX и XII карбоангидразы в канцерогенезе и по комбинированному действию ингибиторов карбоангидраз с противоопухолевыми препаратами.

1. Neri D., Supuran C. T. Interfering with pH regulation in tumours as a therapeutic strategy // Nature Reviews Drug Discovery. Nature Publishing Group. – 2011. – Vol. 10. – № 10. – P. 767–777.

2. Benej M., Pastorekova S., Pastorek J. Carbonic Anhydrase IX: regulation and role in cancer // Subcell. Biochem. – 2014. – Vol. 75. – P. 199–219.

3. Gilmour K. M. Perspectives on carbonic anhydrase // Comp. Biochem. Physiol. Part A Mol. Integr. Physiol. – 2010. – Vol. 157, № 3. – P. 193–197.

4. McKenna R., Frost S. C. Overview of the carbonic anhydrase family // Sub-cellular biochemistry. United States. – 2014. – Vol. 75. – P. 3–5.

5. Zamanova S., Shabana A. M., Mondal U. K., Ilies M. A. Carbonic anhydrases as disease markers // Expert Opin. Ther. Pat. – 2019. – Vol. 29, № 7. – P. 509–533.

6. Lomelino C. L., Andring J. T., McKenna R. Crystallography and Its Impact on Carbonic Anhydrase Research // Int. J. Med. Chem. – 2018. – Vol. 2018. – P. 1–21.

7. Alterio V., Hilvo M., Di Fiore A. et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX // Proc. Natl. Acad. Sci. U. S. A. – 2009. – Vol. 106, № 38. – P. 16233–16238.

8. Whittington D. A., Waheed A., Ulmasov B. et al. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells // Proc. Natl. Acad. Sci. U. S. A. – 2001. – Vol. 98, № 17. – P. 9545–9550.

9. Ilies M. A., Winum J. Y. Carbonic anhydrase inhibitors for the treatment of tumors: Therapeutic, immunologic, and diagnostic tools targeting isoforms IX and XII // Carbonic Anhydrases: Biochemistry and Pharmacology of an Evergreen Pharmaceutical Target. Elsevier Inc. – 2019. – Vol. 2. – P. 331–365.

10. Chiche J., Ilc K., Laferrière J. et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH // Cancer Res. – 2009. – Vol. 69, № 1. – P. 358–368.

11. Terry S., Faouzi Zaarour R., Hassan Venkatesh G. et al. Role of hypoxic stress in regulating tumor immunogenicity, resistance and plasticity // Int. J. Mol. Sci. – 2018. – Vol. 19, № 10. – P. 3044–3063.

12. Parks S.K., Chiche J., Pouyssegur J. pH control mechanisms of tumor survival and growth // J. Cell. Physiol. United States. – 2011. – Vol. 226, № 2. – P. 299–308.

13. Pastorekova S., Gillies R. J. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond // Cancer Metastasis Rev. Cancer and Metastasis Reviews. – 2019. – Vol. 38, № 1–2. – P. 65–77.

14. Ames S., Pastorekova S., Becker H. M. The proteoglycan-like domain of carbonic anhydrase IX mediates non-catalytic facilitation of lactate transport in cancer cells // Oncotarget. – 2018. – Vol. 9, № 46. – P. 27940–27957.

15. Raghunand N., Gatenby R. A., Gillies R. J. Microenvironmental and cellular consequences of altered blood flow in tumours // Br. J. Radiol. England. – 2003. – Vol. 76. – P. 11–22.

16. Gatenby R. A., Gillies R. J. A microenvironmental model of carcinogenesis // Nat. Rev. Cancer. England. – 2008. – Vol. 8, № 1. – P. 56–61.

17. Riemann A., Rauschner M., Gießelmann M. et al. Extracellular acidosis modulates the expression of Epithelial-Mesenchymal Transition (EMT) markers and adhesion of epithelial and tumor cells // Neoplasia. – 2019. – Vol. 21, № 5. – P. 450–458.

18. Tonissen K. F., Poulsen S. A. Carbonic anhydrase XII inhibition overcomes P- glycoprotein-mediated drug resistance: A potential new combination therapy in cancer // Cancer Drug Resist. – 2021. – Vol. 4, № 2. – P. 343–355.

19. Supuran C. T. Advances in structure-based drug discovery of carbonic anhydrase inhibitors // Expert Opin. Drug Discov. Taylor & Francis. – 2017. – Vol. 12, № 1. – P. 61–88.

20. Eldehna W. M., Nocentini A., Al-Rashood S. T. et al. Tumor-associated carbonic anhydrase isoform IX and XII inhibitory properties of certain isatin-bearing sulfonamides endowed with in vitro antitumor activity towards colon cancer // Bioorg. Chem. Elsevier. – 2018. – Vol. 81. – P. 425–432.

21. El-Gazzar M. G., Nafie N. H., Nocentini A. et al. Carbonic anhydrase inhibition with a series of novel benzenesulfonamide-triazole conjugates // J. Enzyme Inhib. Med. Chem. Taylor & Francis. – 2018. – Vol. 33, № 1. – P. 1565–1574.

22. Nocentini A., Bua S., Lomelino C. L. et al. Discovery of new sulfonamide carbonic anhydrase IX inhibitors incorporating nitrogenous dases // ACS Med. Chem. Lett. – 2017. – Vol. 8, № 12. – P. 1314–1319.

23. Supuran C. T. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors // Expert Opin. Investig. Drugs. England. – 2018. – Vol. 27, № 12. – P. 963–970.

24. Kurt B. Z., Dag A., Doğan B. et al. Synthesis, biological activity and multiscale molecular modeling studies of bis-coumarins as selective carbonic anhydrase IX and XII inhibitors with effective cytotoxicity against hepatocellular carcinoma // Bioorg. Chem. Elsevier. – 2019. – Vol. 87. – P. 838–850.

25. Bonardi A., Falsini M., Catarzi D. et al. Structural investigations on coumarins leading to chromeno[4,3- c]pyrazol-4-ones and pyrano[4,3-c]pyrazol-4-ones: New scaffolds for the design of the tumor-associated carbonic anhydrase isoforms IX and XII // Eur. J. Med. Chem. – 2018. – Vol. 146. – P. 47–59.

26. Angeli A., Trallori E., Carta F. et al. Heterocoumarins Are Selective Carbonic Anhydrase IX and XII Inhibitors with Cytotoxic Effects against Cancer Cells Lines // ACS Med. Chem. Lett. – 2018. – Vol. 9, № 9. – P. 947–951.

27. Cadoni R., Pala N., Lomelino C. et al. Exploring Heteroaryl-pyrazole Carboxylic Acids as Human Carbonic Anhydrase XII Inhibitors // ACS Med. Chem. Lett. – 2017. – Vol. 8, № 9. – P. 941–946.

28. Nocentini A., Lucidi A., Perut F. et al. α-diketocarboxylic acids and their esters act as carbonic anhydrase IX and XII selective inhibitors: rapid-communication // ACS Med. Chem. Lett. American Chemical Society. – 2019. – Vol. 10, № 4. – P. 661–665.

29. Ivanova J., Leitans J., Tanc M. et al. X-ray crystallography-promoted drug design of carbonic anhydrase inhibitors // Chem. Commun. Royal Society of Chemistry. – 2015. – Vol. 51, № 33. – P. 7108–7111.

30. Coviello V., Marchi B., Sartini S. et al. 1,2-benzisothiazole derivatives bearing 4-, 5-, or 6- alkyl/arylcarboxamide moieties inhibit Carbonic Anhydrase Isoform IX (CAIX) and cell proliferation under hypoxic conditions // J. Med. Chem. – 2016. – Vol. 59, № 13. – P. 6547–6552.

31. Bua S., Lomelino C. L., Murray A. B. et al. “a Sweet Combination”: developing saccharin and acesulfame K structures for selectively targeting the tumor-associated carbonic anhydrases IX and XII // J. Med. Chem. – 2020. – Vol. 63, № 1. – P. 321–333.

32. Riemann A., Güttler A., Haupt V. et al. Inhibition of Carbonic Anhydrase IX by Ureidosulfonamide Inhibitor U104 Reduces prostate cancer cell growth, but does not modulate daunorubicin or cisplatin cytotoxicity // Oncol. Res. – 2018. – Vol. 26. – № 2. – P. 191–200.

33. Bernardino R. L., Dias T. R., Moreira B. P. et al. Carbonic anhydrases are involved in mitochondrial biogenesis and control the production of lactate by human Sertoli cells // FEBS J. England. – 2019. – Vol. 286, № 7. – P. 1393–1406.

34. McDonald P. C., Chia S., Bedard P. L. et al. A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors // Am. J. Clin. Oncol. – 2020. – Vol. 43, № 7. – P. 484–490.

35. Gieling R. G., Babur M., Mamnani L. et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts // J. Med. Chem. – 2012. – Vol. 55, №11. – P. 5591–5600.

36. Bryant J. L., Gieling R. G., Meredith S. L. et al. Novel carbonic anhydrase IX-targeted therapy enhances the antitumour effects of cisplatin in small cell lung cancer // Int. J. cancer. United States. – 2018. – Vol. 142, № 1. – P. 191–201.

37. Cuffaro D., Nuti E., Rossello A. An overview of carbohydrate-based carbonic anhydrase inhibitors // J. Enzyme Inhib. Med. Chem. Taylor & Francis. – 2020. – Vol. 35, № 1. – P. 1906–1922.

38. Supuran C. T. Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors // Expert Opin. Investig. Drugs. Taylor & Francis. – 2021. – Vol. 30, № 12. – P. 1197–1208.

39. Andreucci E., Ruzzolini J., Peppicelli S. et al. The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy // J. Enzyme Inhib. Med. Chem. Taylor & Francis. – 2019. – Vol. 34, № 1. – P. 117–123.

40. Boyd N. H., Walker K., Fried J. et al. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo // JCI Insight. – 2017. – Vol. 2, № 24. – P. 1–16.

41. Van Kuijk S. J., Gieling R. G., Niemans R. et al. The sulfamate small molecule CAIX inhibitor S4 modulates doxorubicin efficacy // PLoS One. – 2016. – Vol. 11, № 8. – P. 1–14.

42. Ward C., Meehan J., Mullen P. et al. Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models // Oncotarget. – 2015. – Vol. 6, № 28. – P. 24856–24870.

43. McDonald P. C., Chafe S. C., Brown W. S. et al. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia // Gastroenterology. – 2019. – Vol. 157, № 3. – P. 823–837.

44. Kleeff J., Korc M., Apte M. et al. Pancreatic cancer // Nat. Rev. Dis. Prim. Macmillan Publishers Limited. – 2016. – Vol. 2. – P. 1–23.

45. Lee K. E., Spata M., Bayne L. J. et al. Hif1a deletion reveals pro-neoplastic function of B cells in pancreatic neoplasia // Cancer Discov. – 2016. – Vol. 6, № 3. – P. 256–269.

46. Petrenko M., Güttler A., Funtan A. et al. Combined 3-O-acetylbetulin treatment and carbonic anhydrase IX inhibition results in additive effects on human breast cancer cells // Chem. Biol. Interact. – 2021. – Vol. 333. – P. 109326–109335.

47. Hedlund E. M. E., McDonald P. C., Nemirovsky O. et al. Harnessing induced essentiality: Targeting carbonic anhydrase IX and angiogenesis reduces lung metastasis of triple negative breast cancer xenografts // Cancers (Basel). – 2019. – Vol. 11, № 7. – P. 1002–1020.

48. Chiche J., Brahimi-Horn M.C., Pouysségur J. Tumour hypoxia induces a metabolic shift causing acidosis: A common feature in cancer // J. Cell. Mol. Med. – 2010. – Vol. 14, № 4. – P. 771–794.

49. Bellot G., Garcia-Medina R., Gounon P. et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains // Mol. Cell. Biol. – 2009. – Vol. 29, № 10. – P. 2570–2581.

50. Chafe S. C., Vizeacoumar F. S., Venkateswaran G. et al. Genome-wide synthetic lethal screen unveils novel CAIXNFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors // Sci. Adv. – 2021. – Vol. 7, № 35. – P. 1–16.